Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Common Equity (2016 - 2025)

Historic Common Equity for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $372.8 million.

  • Myriad Genetics' Common Equity fell 4905.02% to $372.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.8 million, marking a year-over-year decrease of 4905.02%. This contributed to the annual value of $701.1 million for FY2024, which is 1048.26% down from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Common Equity is $372.8 million, which was down 4905.02% from $388.1 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Common Equity high stood at $968.6 million for Q3 2021, and its period low was $372.8 million during Q3 2025.
  • Moreover, its 5-year median value for Common Equity was $783.2 million (2023), whereas its average is $781.6 million.
  • In the last 5 years, Myriad Genetics' Common Equity surged by 985.24% in 2021 and then plummeted by 4905.02% in 2025.
  • Myriad Genetics' Common Equity (Quarter) stood at $967.8 million in 2021, then decreased by 8.47% to $885.8 million in 2022, then fell by 11.58% to $783.2 million in 2023, then decreased by 10.48% to $701.1 million in 2024, then tumbled by 46.83% to $372.8 million in 2025.
  • Its last three reported values are $372.8 million in Q3 2025, $388.1 million for Q2 2025, and $704.9 million during Q1 2025.